Why is Novo Nordisk charging Americans with diabetes and obesity outrageously high prices for Ozempic and Wegovy? : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eighteenth Congress, second session, : on Examining Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity, September 24, 2024.